Diabetes: Is there a future for Pharmacogenomics guided treatment?

Ewan Pearson (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)
166 Downloads (Pure)


Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment—with patients being able to transition from insulin to sulfonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors but highlights that these variants will only be of clinical utility when the genotype is already known at the point of prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm shift—that of preemptive panel genotyping and use of clinical decision support tools to assimilate this genetic information with other clinical phenotypic data and to present this information simply to the prescriber. Given the recent dramatic fall in genotyping costs, this future is not far off.

Original languageEnglish
Pages (from-to)329-337
Number of pages9
JournalClinical Pharmacology & Therapeutics
Issue number2
Early online date23 Apr 2019
Publication statusPublished - 12 Jul 2019

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Diabetes: Is there a future for Pharmacogenomics guided treatment?'. Together they form a unique fingerprint.

Cite this